WT1 and acute myeloid leukemia: We previously performed a phase I/II clinical trial to examine the safety of as well as the clinical and immunological responses to a WT1 HLA class I peptide vaccine for HLA-A*24:02-positive patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and breast and lung cancers [19, 20].